Who are AXS-05's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/axs-05.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AXS-05 — Competitive Intelligence Brief

AXS-05 (AXS-05) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antidepressant (NMDA antagonist + norepinephrine-dopamine reuptake inhibitor). Area: Psychiatry/Neurology.

marketed Combination antidepressant (NMDA antagonist + norepinephrine-dopamine reuptake inhibitor) Sigma-1 receptor, NMDA receptor, norepinephrine transporter, dopamine transporter Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AXS-05 (AXS-05) — Axsome Therapeutics, Inc.. AXS-05 is a combination of dextromethorphan and bupropion that enhances serotonergic and noradrenergic neurotransmission while modulating NMDA receptor activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AXS-05 TARGET	AXS-05	Axsome Therapeutics, Inc.	marketed	Combination antidepressant (NMDA antagonist + norepinephrine-dopamine reuptake inhibitor)	Sigma-1 receptor, NMDA receptor, norepinephrine transporter, dopamine transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antidepressant (NMDA antagonist + norepinephrine-dopamine reuptake inhibitor) class)

Axsome Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AXS-05 — Competitive Intelligence Brief. https://druglandscape.com/ci/axs-05. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab